CompletedPhase 3

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

Spain318 participantsStarted 2017-10-20

Plain-language summary

The purpose of this study is to determine whether Medroxyprogesterone Acetate (MPA) administration in follicular phase prevents premature luteinization with equal efficiency as GnRH antagonists and otains similar clinical results in oocyte donation.

Who can participate

Age range18 Years – 35 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy ovaries and uterus, with no organic pathology
✓. Ovaries without polycystic aspect
✓. Antral Follicle Count \> 12 in the sum of both ovaries
✓. Normal Karyotype
✓. Negative results in infectious illness screening (Hepatitis B Virus; Hepatitis C Virus, VIH Virus Syphilis)
✓. Results within range of general analysis of hemogram, hemostasia y biochemistry.

What they're measuring

Compare number of oocytes using GnRH antagonist versus PMA.

Timeframe: 36 hours: from triggering until Oocyte retrieval

Trial details

NCT IDNCT03300960

SponsorInstituto Valenciano de Infertilidad, IVI VALENCIA

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-06-25

View on ClinicalTrials.gov More Infertility trials